CR Bard execs know they have a gorilla of a competitor in the proposed $43 billion Medtronic acquisition of Covidien, particularly in the vascular business. They aren’t predicting the effects of that business combination on Bard, ...
Tags: CR Bard Eyes, Health, Medicine